Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 21, 2022 08:00 ET | Source: Arch Oncology

Arch Oncology Receives U.S. FDA Orphan Drug Designation for AO-176, a Next-Generation Anti-CD47 IgG2 Antibody, for the Treatment of Multiple Myeloma

BRISBANE, Calif. and ST. LOUIS, Jan. 21, 2022 (GLOBE NEWSWIRE) -- Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 biologic...
August 02, 2021 08:00 ET | Source: Arch Oncology

Arch Oncology Strengthens Medical and Clinical Leadership Teams with Key Appointments

– Seasoned oncology leaders Louie Naumovski, M.D., Ph.D., appointed as Chief Medical Officer; Amit Agarwal, M.D., Ph.D. as Senior V.P., Clinical Development and Steve DeMattos as Senior V.P., Clinical...
April 27, 2021 07:00 ET | Source: Arch Oncology

Arch Oncology Secures $105 Million Series C Financing

– Proceeds to support clinical progress of differentiated anti-CD47 candidate AO-176 for patients with solid tumors and hematologic malignancies – – Series C co-led by new investors Eventide Asset...
April 10, 2021 08:31 ET | Source: Arch Oncology

Arch Oncology Presents New Preclinical T-ALL Data on Highly-differentiated Anti-CD47 Antibody AO-176 at AACR 2021

BRISBANE, Calif., April 10, 2021 (GLOBE NEWSWIRE) -- Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today...
April 07, 2021 08:00 ET | Source: Arch Oncology

Arch Oncology Appoints Laurence Blumberg, M.D. President and CEO

BRISBANE, Calif. and ST. LOUIS, April 07, 2021 (GLOBE NEWSWIRE) -- Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody...
March 10, 2021 17:09 ET | Source: Arch Oncology

Arch Oncology Announces Two New Preclinical Data Presentations on Highly Differentiated Anti-CD47 Antibody AO-176 at AACR 2021

-- Two presentations to highlight AO-176’s potential in lymphoma and T-ALL -- BRISBANE, Calif. and ST. LOUIS, March 10, 2021 (GLOBE NEWSWIRE) -- Arch Oncology, Inc., a clinical-stage...
February 16, 2021 09:00 ET | Source: Arch Oncology

Arch Oncology to Participate in Upcoming Conferences

BRISBANE, Calif. and ST. LOUIS, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody...
February 09, 2021 09:00 ET | Source: Arch Oncology

Arch Oncology to Collaborate with Merck on Phase 1/2 Clinical Trial of Anti-CD47 Antibody AO-176 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Select Solid Tumors

BRISBANE, Calif. and ST. LOUIS, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody...
January 06, 2021 09:00 ET | Source: Arch Oncology

Arch Oncology to Present at 39th Annual J.P. Morgan Healthcare Conference

BRISBANE, Calif. and ST. LOUIS, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody...
December 07, 2020 09:00 ET | Source: Arch Oncology

Arch Oncology Announces First Patient Dosed in Phase 1/2 Clinical Trial of Anti-CD47 Antibody AO-176 in Multiple Myeloma

-- First Dedicated Clinical Trial of an Anti-CD47 Antibody in Multiple Myeloma ---- At ASH 2020, New Preclinical Data Presented on AO-176 in Multiple Myeloma -- BRISBANE, Calif. and ST. LOUIS, Dec. ...